Incredible: Fosun Pharma can earn 1.5 billion by a single robot?

GSK and other multinational pharmaceutical companies have sluggish performance in China

After the “labor pain” of the medical revolution in 2015, 2016 is still difficult for multinational pharmaceutical companies that are still in transition in China. In the context of strengthening core business, layoffs, business divestiture and mergers and acquisitions, negotiations to cut prices and pay attention to the grassroots have become the "keywords" of multinational pharmaceutical companies in the first half of this year.

For example, a few days ago, Bristol-Myers Squibb and Johnson & Johnson's nearly a thousand layoffs; GSK announced the sale of shares in Nanjing Meirui Pharmaceutical held in China, the Meirui factory and local production and supply operations related to three urinary products; tenofovir The monthly average drug cost of gefitinib is lowered; Sanofi defines the domestic grassroots market as one of the “basic strategies” of the enterprise, and Lilly launches the LEAP project in the grassroots township hospital through the new department of diabetes basics.

Despite the fact that multinational pharmaceutical companies are in China, the performance of China's medical and health industry has also improved in 2016. According to public data, as of August 25, a total of 22 multinational pharmaceutical companies announced their 2016 performance in China.

Among them, the total sales of these 22 multinational pharmaceutical companies were 64.768 billion yuan, with an average growth rate of 9.74%. The 15 companies, led by Takeda (123.36% increase), etc., have double-digit growth.

Sales performance of multinational pharmaceutical companies in China in the first half of 2016

In addition, Xiao Bian also found that GSK, Baxter, and Aibowei showed negative growth.

Among them, Aberdeen's negative growth rate exceeded 42.73%. Investigating the cause, mainly the Aibowei treatment of rheumatoid arthritis and ankylosing spondylitis "Xiu Meile" failed to win the bid, appeared in the medical insurance catalog. This is undoubtedly a fatal blow to its sales.

Fine Chemicals

Shanghai J.Shine Co.,Ltd , https://www.jshinechem.com